Literature DB >> 25242594

Intrauterine devices and endometrial cancer risk: a pooled analysis of the Epidemiology of Endometrial Cancer Consortium.

Ashley S Felix1, Mia M Gaudet, Carlo La Vecchia, Christina M Nagle, Xiao Ou Shu, Elisabete Weiderpass, Hans Olov Adami, Shirley Beresford, Leslie Bernstein, Chu Chen, Linda S Cook, Immaculata De Vivo, Jennifer A Doherty, Christine M Friedenreich, Susan M Gapstur, Dierdre Hill, Pamela L Horn-Ross, James V Lacey, Fabio Levi, Xiaolin Liang, Lingeng Lu, Anthony Magliocco, Susan E McCann, Eva Negri, Sara H Olson, Julie R Palmer, Alpa V Patel, Stacey Petruzella, Jennifer Prescott, Harvey A Risch, Lynn Rosenberg, Mark E Sherman, Amanda B Spurdle, Penelope M Webb, Lauren A Wise, Yong-Bing Xiang, Wanghong Xu, Hannah P Yang, Herbert Yu, Anne Zeleniuch-Jacquotte, Louise A Brinton.   

Abstract

Intrauterine devices (IUDs), long-acting and reversible contraceptives, induce a number of immunological and biochemical changes in the uterine environment that could affect endometrial cancer (EC) risk. We addressed this relationship through a pooled analysis of data collected in the Epidemiology of Endometrial Cancer Consortium. We combined individual-level data from 4 cohort and 14 case-control studies, in total 8,801 EC cases and 15,357 controls. Using multivariable logistic regression, we estimated pooled odds ratios (pooled-ORs) and 95% confidence intervals (CIs) for EC risk associated with ever use, type of device, ages at first and last use, duration of use and time since last use, stratified by study and adjusted for confounders. Ever use of IUDs was inversely related to EC risk (pooled-OR = 0.81, 95% CI = 0.74-0.90). Compared with never use, reduced risk of EC was observed for inert IUDs (pooled-OR = 0.69, 95% CI = 0.58-0.82), older age at first use (≥ 35 years pooled-OR = 0.53, 95% CI = 0.43-0.67), older age at last use (≥ 45 years pooled-OR = 0.60, 95% CI = 0.50-0.72), longer duration of use (≥ 10 years pooled-OR = 0.61, 95% CI = 0.52-0.71) and recent use (within 1 year of study entry pooled-OR = 0.39, 95% CI = 0.30-0.49). Future studies are needed to assess the respective roles of detection biases and biologic effects related to foreign body responses in the endometrium, heavier bleeding (and increased clearance of carcinogenic cells) and localized hormonal changes.
© 2014 UICC.

Entities:  

Keywords:  contraception; endometrial neoplasm; etiology; pooled analysis

Mesh:

Year:  2014        PMID: 25242594      PMCID: PMC4267918          DOI: 10.1002/ijc.29229

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.316


  75 in total

1.  The effect of a levonorgestrel-releasing intrauterine device on human endometrial oestrogen and progesterone receptors after one year of use.

Authors:  P Zhu; X Liu; H Luo; Z Gu; J Cheng; R Xu; S Lian; S Wu; J Wang
Journal:  Hum Reprod       Date:  1999-04       Impact factor: 6.918

2.  Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study.

Authors:  L A Brinton; M L Berman; R Mortel; L B Twiggs; R J Barrett; G D Wilbanks; L Lannom; R N Hoover
Journal:  Am J Obstet Gynecol       Date:  1992-11       Impact factor: 8.661

3.  High breast cancer incidence rates among California teachers: results from the California Teachers Study (United States).

Authors:  Leslie Bernstein; Mark Allen; Hoda Anton-Culver; Dennis Deapen; Pamela L Horn-Ross; David Peel; Richard Pinder; Peggy Reynolds; Jane Sullivan-Halley; Dee West; William Wright; Al Ziogas; Ronald K Ross
Journal:  Cancer Causes Control       Date:  2002-09       Impact factor: 2.506

4.  Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia.

Authors:  Anne Beate Vereide; Turid Kaino; Georg Sager; Marit Arnes; Anne Ørbo
Journal:  Gynecol Oncol       Date:  2005-12-01       Impact factor: 5.482

Review 5.  Cancer-related inflammation: common themes and therapeutic opportunities.

Authors:  Frances R Balkwill; Alberto Mantovani
Journal:  Semin Cancer Biol       Date:  2011-12-24       Impact factor: 15.707

6.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

Review 7.  Type I and II endometrial cancers: have they different risk factors?

Authors:  Veronica Wendy Setiawan; Hannah P Yang; Malcolm C Pike; Susan E McCann; Herbert Yu; Yong-Bing Xiang; Alicja Wolk; Nicolas Wentzensen; Noel S Weiss; Penelope M Webb; Piet A van den Brandt; Koen van de Vijver; Pamela J Thompson; Brian L Strom; Amanda B Spurdle; Robert A Soslow; Xiao-ou Shu; Catherine Schairer; Carlotta Sacerdote; Thomas E Rohan; Kim Robien; Harvey A Risch; Fulvio Ricceri; Timothy R Rebbeck; Radhai Rastogi; Jennifer Prescott; Silvia Polidoro; Yikyung Park; Sara H Olson; Kirsten B Moysich; Anthony B Miller; Marjorie L McCullough; Rayna K Matsuno; Anthony M Magliocco; Galina Lurie; Lingeng Lu; Jolanta Lissowska; Xiaolin Liang; James V Lacey; Laurence N Kolonel; Brian E Henderson; Susan E Hankinson; Niclas Håkansson; Marc T Goodman; Mia M Gaudet; Montserrat Garcia-Closas; Christine M Friedenreich; Jo L Freudenheim; Jennifer Doherty; Immaculata De Vivo; Kerry S Courneya; Linda S Cook; Chu Chen; James R Cerhan; Hui Cai; Louise A Brinton; Leslie Bernstein; Kristin E Anderson; Hoda Anton-Culver; Leo J Schouten; Pamela L Horn-Ross
Journal:  J Clin Oncol       Date:  2013-06-03       Impact factor: 44.544

Review 8.  Neoplasia with use of intrauterine devices.

Authors:  Kathryn M Curtis; Polly A Marchbanks; Herbert B Peterson
Journal:  Contraception       Date:  2007-02-20       Impact factor: 3.375

9.  The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk.

Authors:  T J Key; M C Pike
Journal:  Br J Cancer       Date:  1988-02       Impact factor: 7.640

10.  Intrauterine device use and risk of endometrial cancer.

Authors:  F Parazzini; C La Vecchia; S Moroni
Journal:  Br J Cancer       Date:  1994-10       Impact factor: 7.640

View more
  10 in total

Review 1.  Addressing the Role of Obesity in Endometrial Cancer Risk, Prevention, and Treatment.

Authors:  Michaela A Onstad; Rosemarie E Schmandt; Karen H Lu
Journal:  J Clin Oncol       Date:  2016-11-07       Impact factor: 44.544

2.  Cancer Progress and Priorities: Uterine Cancer.

Authors:  Ashley S Felix; Louise A Brinton
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-09       Impact factor: 4.254

3.  Complications of Pregnancy and the Risk of Developing Endometrial or Ovarian Cancer: A Case-Control Study.

Authors:  Yang Liu; Xingyu Chen; Jiayi Sheng; Xinyi Sun; George Qiaoqi Chen; Min Zhao; Qi Chen
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-30       Impact factor: 5.555

4.  The risk of using intrauterine devices to benign reproductive system conditions in postmenopausal women: A case control study.

Authors:  Xiaohua Zhang; Liping Xiao; Haoping Zhu; Linan Cheng
Journal:  J Res Med Sci       Date:  2016-03-15       Impact factor: 1.852

Review 5.  Prevention Strategies in Endometrial Carcinoma.

Authors:  Michelle L MacKintosh; Emma J Crosbie
Journal:  Curr Oncol Rep       Date:  2018-11-13       Impact factor: 5.075

Review 6.  Contraception During Perimenopause: Practical Guidance.

Authors:  Giovanni Grandi; Pierluigi Di Vinci; Alice Sgandurra; Lia Feliciello; Francesca Monari; Fabio Facchinetti
Journal:  Int J Womens Health       Date:  2022-07-15

Review 7.  Lifestyle changes and the risk of developing endometrial and ovarian cancers: opportunities for prevention and management.

Authors:  Anna L Beavis; Anna Jo Bodurtha Smith; Amanda Nickles Fader
Journal:  Int J Womens Health       Date:  2016-05-23

8.  Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Nummer 032/034-OL, April 2018) - Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer.

Authors:  Günter Emons; Eric Steiner; Dirk Vordermark; Christoph Uleer; Nina Bock; Kerstin Paradies; Olaf Ortmann; Stefan Aretz; Peter Mallmann; Christian Kurzeder; Volker Hagen; Birgitt van Oorschot; Stefan Höcht; Petra Feyer; Gerlinde Egerer; Michael Friedrich; Wolfgang Cremer; Franz-Josef Prott; Lars-Christian Horn; Heinrich Prömpeler; Jan Langrehr; Steffen Leinung; Matthias W Beckmann; Rainer Kimmig; Anne Letsch; Michael Reinhardt; Bernd Alt-Epping; Ludwig Kiesel; Jan Menke; Marion Gebhardt; Verena Steinke-Lange; Nils Rahner; Werner Lichtenegger; Alain Zeimet; Volker Hanf; Joachim Weis; Michael Mueller; Ulla Henscher; Rita K Schmutzler; Alfons Meindl; Felix Hilpert; Joan Elisabeth Panke; Vratislav Strnad; Christiane Niehues; Timm Dauelsberg; Peter Niehoff; Doris Mayr; Dieter Grab; Michael Kreißl; Ralf Witteler; Annemarie Schorsch; Alexander Mustea; Edgar Petru; Jutta Hübner; Anne Derke Rose; Edward Wight; Reina Tholen; Gerd J Bauerschmitz; Markus Fleisch; Ingolf Juhasz-Boess; Lax Sigurd; Ingo Runnebaum; Clemens Tempfer; Monika J Nothacker; Susanne Blödt; Markus Follmann; Thomas Langer; Heike Raatz; Simone Wesselmann; Saskia Erdogan
Journal:  Geburtshilfe Frauenheilkd       Date:  2018-10-19       Impact factor: 2.915

9.  Contraception for Adolescents

Authors:  Nicole Todd; Amanda Black
Journal:  J Clin Res Pediatr Endocrinol       Date:  2020-02-06

10.  Beyond the numbers-understanding women's experiences of accessing care for abnormal uterine bleeding (AUB): a qualitative study.

Authors:  Claire Henry; Regina Jefferies; Alec Ekeroma; Sara Filoche
Journal:  BMJ Open       Date:  2020-11-17       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.